explore -WSS

explore

author：leisure time 2025-09-02 08:20:36 - browse：441

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Covid vaccines: Private market messier than government rollout

WSS

After a drawn out lobbying fight, ARPA

Data show record exodus of life scientists from academia

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Researchers use wearables data and AI to predict preterm birth risk

Covid vaccines: Private market messier than government rollout

Biogen shutters digital health group, ends Apple study, in cost cutting move

knowledge

explore

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Intercept Pharmaceuticals sells itself for less than $1 billion

United colonoscopy coverage change 'may cost lives,' doctors say

Kaiser Permanente unions announce official strike date

How to save PrEP access — and even expand it

Pregnancy ages women, but effects reverse after delivery

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA advisers vote against ALS treatment from BrainStorm

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Health tech startups drop sharply from 2021 highs

Wikipedia

Why do women spend more than men on medical expenses?

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Mirador, a new biotech startup, launches with $400 million

Paxlovid should be available without a positive Covid test

How the Dana

knowledge

knowledge

leisure time

entertainment